September 8, 2011. National Research Center of Women & Families Brandel France de Bravo testifies at the FDA meeting on transvaginal mesh.
Read More »On Medical Treatments & Products
NCHR Testimony on Transvaginal Mesh
September 9, 2011. We agree with the FDA that serious adverse events from mesh are NOT rare. No man or woman wants to suffer from incontinence, but there is no doubt that the terribly painful complications can be much worse than the incontinence that initially led to surgery. And, those complications are often impossible to repair.
Read More »NCHR Testimony on Bisphosphonates
September 9, 2011. NCHR president Diana Zuckerman testifies before the FDA Joint Meeting of the Advisory Committee for Reproductive Health Drugs and the Drug Safety and Risks Management Advisory Committee.
Read More »NCHR Testimony at FDA on Avastin
June 28, 2011. National Research Center of Women & Families President Diana Zuckerman testifies at the FDA meeting on Avastin.
Read More »NCHR Testimony at a House of Representatives Briefing on Medical Devices
May 17, 2011. Lives could be saved and patients would spend less time in the hospital if the FDA implemented the law as required by using the PMA process for all devices that are potentially dangerous in predictable ways.
Read More »